Postoperative Recovery

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AlkahestCA - San Carlos

1 program

GRF6021Phase 22 trials

Active Trials

NCT03981419Completed38Est. Mar 2021

NCT03713957Completed79Est. Jul 2020

City TherapeuticsMA - Cambridge

1 program

reducing anticholinergic burdenPHASE_41 trial

Active Trials

NCT06349057CompletedEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

City Therapeuticsreducing anticholinergic burden

AlkahestGRF6021

Clinical Trials (3)

Total enrollment: 117 patients across 3 trials

NCT06349057 City Therapeuticsreducing anticholinergic burden

The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery

Start: Jan 2024Est. completion: Dec 2025

Phase 4Completed

NCT03981419 AlkahestGRF6021

A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty

Start: Jul 2019Est. completion: Mar 202138 patients

Phase 2Completed

NCT03713957 AlkahestGRF6021

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Start: Nov 2018Est. completion: Jul 202079 patients

Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.